Home > Insider Trading > Filing (0001261380-16-000083)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006045	Iridex Corp	IRIX	Electromedical & Electrotherapeutic Apparatus (3845)	770210467

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1304121	Ronald Steckel	1212 Terra Bella Avenue Mountain View CA 94043	Vp, Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-05-17	2,083	$3.99	68,958	No	4	M	Direct
Common Stock	Disposition	2016-05-17	2,083	$12.82	66,875	No	4	S	Direct
Common Stock	Acquisiton	2016-05-17	1,250	$3.86	68,125	No	4	M	Direct
Common Stock	Disposition	2016-05-17	1,250	$12.82	66,875	No	4	S	Direct
Common Stock	Disposition	2016-05-17	1,250	$12.79	65,625	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option Right to Buy	Disposition	2016-05-17	2,083	$0.00	2,083	$3.99
Common Stock	Stock Option Right to Buy	Disposition	2016-05-17	1,250	$0.00	1,250	$3.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-04-16	2019-04-16	No	4	M	Direct
5,000	2013-02-01	2019-12-13	No	4	M	Direct

Footnotes

The sales price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold, ranging from $12.67 to $12.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sales price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold, ranging from $12.67 to $12.9 per share. Upon request by the Commission staff, the Issuer, or a security holder of Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
This option was granted pursuant to IRIDEX Corporation's 2008 Equity Incentive Plan and is exempt to Rule 16b-3.
The shares shall vest as follows: 12/48ths of the shares shall vest 12 months after the Vesting Commencement Date and 1/48th of the shares shall vest each month thereafter.
The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest each month.